Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Wiela-Hojeńska

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Acta Poloniae Pharmaceutica|August 2, 2016
ECONOMIC ISSUES IN THERAPEUTIC DRUG MONITORINGPaweł Petryszyn, Anna Wiela-Hojeńska
International Journal of Molecular Sciences|June 2, 2021
Pseudoephedrine-Benefits and RisksKrystyna Głowacka, Anna Wiela-Hojeńska
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego|April 26, 2003
[Bioavailability and its significance in pharmacotherapy]Anna Wiela-Hojeńska, Krystyna Orzechowska-Juzwenko
International Journal of Molecular Sciences|April 30, 2021
Nephrotoxicity of Herbal Products in Europe-A Review of an Underestimated ProblemKatarzyna Kiliś-Pstrusińska, Anna Wiela-Hojeńska
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|November 10, 2018
The importance of the polymorphisms of the ABCB1 gene in disease susceptibility, behavior and response to treatment in inflammatory bowel disease: A literature reviewPaweł W Petryszyn, Anna Wiela-Hojeńska
Molecules (Basel, Switzerland)|December 24, 2021
Antibiotics and the Nervous System-Which Face of Antibiotic Therapy Is Real, Dr. Jekyll (Neurotoxicity) or Mr. Hyde (Neuroprotection)?Magdalena Hurkacz, Lukasz Dobrek, Anna Wiela-Hojeńska
Pharmacogenomics|August 2, 2019
Venlafaxine pharmacogenetics: a comprehensive reviewJustyna Suwała, Marta Machowska, Anna Wiela-Hojeńska
Journal of Clinical Medicine|April 14, 2026
Primary, Secondary and Exploratory Endpoints in Phase 2 and 3 Clinical Trials with Novel Therapies in MASH Cirrhosis: A Systematic ReviewGrzegorz Żurakowski, Anna Wiela-Hojeńska, Paweł Petryszyn
Contemporary Oncology (Poznan, Poland)|April 5, 2017
Comparison of clinical pharmacology of voriconazole and posaconazoleBeata M Sienkiewicz, Łukasz Łapiński, Anna Wiela-Hojeńska
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego|March 1, 2014
[Phytotherapy threats with emphasis on St. John's wort medicines]Jacek Sienkiewicz, Henryk Czarnik-Matusewicz, Anna Wiela-Hojeńska
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Acta Poloniae Pharmaceutica|August 2, 2016
ECONOMIC ISSUES IN THERAPEUTIC DRUG MONITORINGPaweł Petryszyn, Anna Wiela-Hojeńska
International Journal of Molecular Sciences|June 2, 2021
Pseudoephedrine-Benefits and RisksKrystyna Głowacka, Anna Wiela-Hojeńska
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego|April 26, 2003
[Bioavailability and its significance in pharmacotherapy]Anna Wiela-Hojeńska, Krystyna Orzechowska-Juzwenko
International Journal of Molecular Sciences|April 30, 2021
Nephrotoxicity of Herbal Products in Europe-A Review of an Underestimated ProblemKatarzyna Kiliś-Pstrusińska, Anna Wiela-Hojeńska
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|November 10, 2018
The importance of the polymorphisms of the ABCB1 gene in disease susceptibility, behavior and response to treatment in inflammatory bowel disease: A literature reviewPaweł W Petryszyn, Anna Wiela-Hojeńska
Molecules (Basel, Switzerland)|December 24, 2021
Antibiotics and the Nervous System-Which Face of Antibiotic Therapy Is Real, Dr. Jekyll (Neurotoxicity) or Mr. Hyde (Neuroprotection)?Magdalena Hurkacz, Lukasz Dobrek, Anna Wiela-Hojeńska
Pharmacogenomics|August 2, 2019
Venlafaxine pharmacogenetics: a comprehensive reviewJustyna Suwała, Marta Machowska, Anna Wiela-Hojeńska
Journal of Clinical Medicine|April 14, 2026
Primary, Secondary and Exploratory Endpoints in Phase 2 and 3 Clinical Trials with Novel Therapies in MASH Cirrhosis: A Systematic ReviewGrzegorz Żurakowski, Anna Wiela-Hojeńska, Paweł Petryszyn
Contemporary Oncology (Poznan, Poland)|April 5, 2017
Comparison of clinical pharmacology of voriconazole and posaconazoleBeata M Sienkiewicz, Łukasz Łapiński, Anna Wiela-Hojeńska
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego|March 1, 2014
[Phytotherapy threats with emphasis on St. John's wort medicines]Jacek Sienkiewicz, Henryk Czarnik-Matusewicz, Anna Wiela-Hojeńska
Pageof 4